haloperidol has been researched along with Weight Loss in 2 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Weight Loss: Decrease in existing BODY WEIGHT.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Correll, CU | 1 |
| Sheridan, EM | 1 |
| DelBello, MP | 1 |
| Shibley, H | 1 |
| Pelic, C | 1 |
| Kahn, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase[NCT01893229] | Phase 4 | 120 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for haloperidol and Weight Loss
| Article | Year |
|---|---|
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.
Topics: Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Anti-Obesity Agents; Antimanic Agents; Anti | 2010 |
1 other study available for haloperidol and Weight Loss
| Article | Year |
|---|---|
A case of paranoid schizophrenia complicated by scleroderma with associated esophageal dysmotility.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Case Management; Commitment of M | 2008 |